CompletedNCT00261443
A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania
Medication studyAges 18+Multiple countriesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Tuscaloosa, United States · Anaheim, United States and 71 more locationsSee all locations and recruitment
- Activities
- Placebo comparator · Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateSeptember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,270
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, France, Brazil, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00261443
- Official title
Show the full official title
Efficacy of Aripiprazole in Combination With Lithium or Valproate in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients Partially Nonresponsive to Lithium or Valproate Monotherapy
Recruitment & locations
CompletedTuscaloosa, United States · Anaheim, United States · Cerritos, United States
70 more locations
- Costa Mesa, United States
- Long Beach, United States
- National City, United States
- Orange, United States
- Orlando, United States
- Tampa, United States
- Smyrna, United States
- Worcester, United States
- St Louis, United States
- Clementon, United States
- New York, United States
- Staten Island, United States
- Raleigh, United States
- Beachwood, United States
- Cincinnati, United States
- Cleveland, United States
- Dayton, United States
- Portland, United States
- Austin, United States
- Dallas, United States
- DeSoto, United States
- Houston, United States
- Salt Lake City, United States
- Bellevue, United States
- Salvador, Brazil
- Aparecida de Goinia, Brazil
- Pelotas, Brazil
- Rio de Janeiro, Brazil
- São Paulo, Brazil
- Burgas, Bulgaria
- Rousse, Bulgaria
- Rijeka, Croatia
- Split, Croatia
- Zadar, Croatia
- Zagreb, Croatia
- Brno, Czechia
- Havířov, Czechia
- Litoměřice, Czechia
- Prague, Czechia
- Přerov, Czechia
- Nantes, France
- Dole, France
- Hénin-Beaumont, France
- Jonzac, France
- La Seyne-sur-Mer, France
- Marseille, France
- Nîmes, France
- Rennes, France
- Hyderabad, India
- Ahmedabad, India
- Kalyan (West), India
- Nāgūr, India
- Pune, India
- Mangalore, India
- Mumbai, India
- Delhi, India
- New Delhi, India
- Izhevsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tomsk, Russia
- Pretoria, South Africa
- Berea, South Africa
- Durban, South Africa
- Cape Town, South Africa
- Paarl, South Africa
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lithium or Valproate with placebo (PBO) and Lithium or Valproate with Aripiprazole.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me